The effect of dulaglutide on stroke: an exploratory analysis of the REWIND trial
Open accessThe DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
Background Cardiovascular outcome trials have suggested that glucagon-like peptide 1 (GLP-1) receptor agonists might reduce strokes. We analysed the effect of dulaglutide on stroke within the researching cardiovascular events with a weekly incretin in diabetes (REWIND) trial.Methods REWIND was a multicentre, randomised, double-blind, placebo-controlled trial done at 371 sites in 24 countries. Men and women (aged ≥50 years) with established or newly detected type 2 diabetes whose HbA 1c was 9·5% or less (with no lower limit) on stable doses of up to two oral glucose-lowering drugs with or without basal insulin therapy were eligible if their body-mass index was at least 23 kg/m 2. Participants were randomly assigned (1:1) to weekly subcutaneous injections of either masked dulaglutide 1·5 mg or the same volume of masked placebo (containing the same excipients but without dulaglutide). Randomisation was done by a computer-generated random code with an interactive web response system with stratification by site. Participants, investigators, the trial leadership, and all other personnel were masked to treatment allocation until the trial was completed and the database was locked. During the treatment period, participants in both groups were instructed to inject study drug on the same day at around the same time, each week. Strokes were categorised as fatal or non-fatal, and as either ischaemic, haemorrhagic, or undetermined. Stroke severity was assessed using the modified Rankin scale. Participants were seen at 2 weeks, 3 months, 6 months, and then every 3 months for drug dispensing and every 6 months for detailed assessments, until 1200 confirmed primary outcomes accrued. The primary endpoint was the first occurrence of any component of the composite outcome, which comprised non-fatal myocardial infarction, non-fatal stroke, or death from cardiovascular or unknown causes. All analyses were done according to an intention-to-treat strategy that included all randomly assigned participants, irrespective of adherence. The trial is registered with ClinicalTrials.gov, number NCT01394952.Findings Between Aug 18, 2011, and Aug 14, 2013, we screened 12 133 patients, of whom 9901 with type 2 diabetes and additional cardiovascular risk factors were randomly assigned to either dulaglutide (n=4949) or an equal volume of placebo (n=4952). During a median follow-up of 5·4 years, cerebrovascular and other cardiovascular outcomes were ascertained and adjudicated. 158 (3·2%) of 4949 participants assigned to dulaglutide and 205 (4·1%) of 4952 participants assigned to placebo had a stroke during follow-up (hazard ratio [HR] 0·76, 95% CI 0·62-0·94; p=0·010). Dulaglutide reduced ischaemic stroke (0·75, 0·59-0·94, p=0·012) but had no effect on haemorrhagic stroke (1·05, 0·55-1·99; p=0·89). Dulaglutide also reduced the composite of non-fatal stroke or all-cause death (0·88, 0·79-0·98; p=0·017) and disabling stroke (0·74, 0·56-0·99; p=0·042). The degree of disability after stroke did not differ by treatment group.Interpretation Long-term dulaglutide use might reduce clinically relevant ischaemic stroke in people with type 2 diabetes but does not affect stroke severity.Funding Eli Lilly and Company.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Similarly, in the REWIND (Researching cardiovascular Events with a Weekly INcretin in Diabetes) CVOT, an exploratory mediation analysis suggested that HbA1c reduction accounted for approximately 50% of the beneficial effects of dulaglutide on stroke [21].”
From Protection against stroke with glucagon-like peptide-1 receptor agonists: a comprehensive review of potential mechanisms (2022) · cites this paper as [21]
In the citing paper
“An exploratory mediation analysis of stroke outcomes in the REWIND CVOT, in which dulaglutide reduced systolic blood pressure (SBP) by a mean of 1.7 mmHg compared to placebo, found that the blood pressure reduction caused by dulaglutide accounts for around 14% of its effect on stroke risk [21].”
From Protection against stroke with glucagon-like peptide-1 receptor agonists: a comprehensive review of potential mechanisms (2022) · cites this paper as [21]
In the citing paper
“An exploratory mediation analysis of stroke outcomes in the REWIND CVOT, in which dulaglutide reduced systolic blood pressure (SBP) by a mean of 1.7 mmHg compared to placebo, found that the blood pressure reduction caused by dulaglutide accounts for around 14% of its effect on stroke risk [21].”
From Protection against stroke with glucagon-like peptide-1 receptor agonists: a comprehensive review of potential mechanisms (2022) · cites this paper as [21]
In the citing paper
“Although fatal/nonfatal stroke was significantly reduced by 24% and ischemic stroke by 25%, the decrease in fatal stroke or hemorrhagic stroke did not achieve statistical significance.37”
From Benefits of GLP-1 (Glucagon-Like Peptide 1) Receptor Agonists for Stroke Reduction in Type 2 Diabetes: A Call to Action for Neurologists (2022) · cites this paper as [37]
In the citing paper
“The impact of dulaglutide on stroke not differ according to sex, age, history of CVD, HbA1c, systolic blood pressure, or use of statins or renin-angiotensinaldosterone system inhibitors.”
From Benefits of GLP-1 (Glucagon-Like Peptide 1) Receptor Agonists for Stroke Reduction in Type 2 Diabetes: A Call to Action for Neurologists (2022) · cites this paper as [37]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Gerstein, H. C., Colhoun, H. M., Dagenais, G. R., Diaz, R., Lakshmanan, M., Pais, P., Probstfield, J., Riesmeyer, J. S., Riddle, M. C., Rydén, L., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31149-3 · Cited by 3,163
Self-citationKristensen, S. L., Rørth, R., Jhund, P. S., Docherty, K. F., Sattar, N., Preiss, D., Køber, L., Petrie, M. C., & McMurray, J. J. V. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30249-9 · Cited by 1,663
Pioglitazone after Ischemic Stroke or Transient Ischemic Attack
Kernan, W. N., Viscoli, C. M., Furie, K. L., Young, L. H., Inzucchi, S. E., Gorman, M., Guarino, P. D., Lovejoy, A. M., Peduzzi, P. N., Conwit, R., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1506930 · Cited by 1,124
Inzucchi, S. E., Zinman, B., Fitchett, D., Wanner, C., Ferrannini, E., Schumacher, M., Schmoor, C., Ohneberg, K., Johansen, O. E., George, J. T., et al. (2018) · Diabetes Care · doi:10.2337/dc17-1096 · Cited by 740
Gerstein, H. C., Colhoun, H. M., Dagenais, G. R., Diaz, R., Lakshmanan, M., Pais, P., Probstfield, J., Botros, F. T., Riddle, M. C., Rydén, L., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31150-x · Cited by 638
Self-citationAroda, V. R. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13162 · Cited by 253
Glucagon-Like Peptide-1: A Focus on Neurodegenerative Diseases
Grieco, M., Giorgi, A., Gentile, M. C., d’Erme, M., Morano, S., Maras, B., & Filardi, T. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.01112 · Cited by 218
Gerstein, H. C., Colhoun, H. M., Dagenais, G. R., Diaz, R., Lakshmanan, M., Pais, P., Probstfield, J., Riddle, M. C., Rydén, L., Xavier, D., et al. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13028 · Cited by 183
Self-citationJendle, J., Grunberger, G., Blevins, T., Giorgino, F., Hietpas, R. T., & Botros, F. T. (2016) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2810 · Cited by 158
Self-citationZinman, B., Inzucchi, S. E., Lachin, J. M., Wanner, C., Fitchett, D., Kohler, S., Mattheus, M., Woerle, H. J., Broedl, U. C., Johansen, O. E., et al. (2017) · Stroke · doi:10.1161/strokeaha.116.015756 · Cited by 136
Cited by
Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes
Gerstein, H. C., Sattar, N., Rosenstock, J., Ramasundarahettige, C., Pratley, R., Lopes, R. D., Lam, C. S. P., Khurmi, N. S., Heenan, L., Del Prato, S., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2108269 · Cited by 829
Self-citationSGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications
Brown, E., Heerspink, H. J. L., Cuthbertson, D. J., & Wilding, J. P. H. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00536-5 · Cited by 581
GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects
Zhao, X., Wang, M., Wen, Z., Lu, Z., Cui, L., Fu, C., Xue, H., Liu, Y., & Zhang, Y. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.721135 · Cited by 463
“Another study on the effect of dulaglutide on stroke showed that dulaglutide reduced the incidence of stroke in middle-aged and elderly people with T2MD and other cardiovascular risk factors, but it cannot reduce the severity of stroke (88).”
BackgroundBushnell, C., Kernan, W. N., Sharrief, A. Z., Chaturvedi, S., Cole, J. W., Cornwell, W. K., Cosby-Gaither, C., Doyle, S., Goldstein, L. B., Lennon, O., et al. (2024) · Stroke · doi:10.1161/str.0000000000000475 · Cited by 360
Cukierman-Yaffe, T., Gerstein, H. C., Colhoun, H. M., Diaz, R., García-Pérez, L.-E., Lakshmanan, M., Bethel, A., Xavier, D., Probstfield, J., Riddle, M. C., et al. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(20)30173-3 · Cited by 300
Self-citation
Metadata
- Authors
- Gerstein, H. C., Hart, R., Colhoun, H. M., Diaz, R., Lakshmanan, M., Botros, F. T., Probstfield, J., Riddle, M. C., Rydén, L., Atisso, C. M., Dyal, L., Hall, S., Avezum, A., Basile, J., Conget, I., Cushman, W. C., Hancu, N., Hanefeld, M., Jansky, P., Keltai, M., Lanas, F., Leiter, L. A., Lopez-Jaramillo, P., Muñoz, E. G. C., Pogosova, N., Raubenheimer, P. J., Shaw, J. E., Sheu, W. H.-H., & Temelkova-Kurktschiev, T.
- Affiliations
- Population Health Research Institute (CA)
- University of Edinburgh (GB)
- Eli Lilly (United States) (US)
- University of Washington (US)
- Oregon Health & Science University (US)
- Karolinska Institutet (SE)
- Medical University of South Carolina (US)
- Hospital Clínic de Barcelona (ES)
- Memphis VA Medical Center (US)
- Universidad de La Frontera (CL)
- St. Michael's Hospital (CA)
- Universidad de Guadalajara (MX)
- University of Cape Town (ZA)
- Baker Heart and Diabetes Institute (AU)
- Taichung Veterans General Hospital (TW)
- Bulgarian National Bank (BG)
- Corresponding author
- Gerstein, Hertzel C
- ORCID
- Venue
- The Lancet Diabetes & Endocrinology
- Publisher
- Elsevier BV
- Published
- 2020-02
- Volume
- 8
- Issue
- 2
- Pages
- 106-114
- ISSN
- 2213-8587 (ISSN-L)
- OpenAlex
- W3000040775
- Cited by
- 137
- References
- 23
- Citations by year
- 2026: 9 · 2025: 15 · 2024: 29 · 2023: 24 · 2022: 18 · 2021: 27 · 2020: 15
- FWCI
- 15.76
- Type
- journal article
- Language
- en
- Open access
- Licence
- cc-by-nc
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- Locations
- The Lancet Diabetes & Endocrinology (publishedVersion)
- Repositorio Universidad de Santander (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Omeka S (Universidad de La Frontera) (submittedVersion, cc-by-nc-nd)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Clinical Neurology › Acute Ischemic Stroke Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- dulaglutide, stroke, GLP-1 receptor agonists, type 2 diabetes, REWIND trial, ischemic stroke, hemorrhagic stroke, cardiovascular outcomes, modified Rankin Scale, stroke severity, cardiovascular risk factors, myocardial infarction, cardiovascular mortality, type 1 diabetes, type 3 diabetes
- MeSH terms
- Glucagon-Like Peptide-1 Receptor Agonists, Diabetes Mellitus, Type 2, Diabetic Angiopathies, Double-Blind Method, Glucagon-Like Peptides, Female, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Immunoglobulin Fc Fragments, Male, Middle Aged, Prospective Studies, Recombinant Fusion Proteins, Treatment Outcome, Stroke, Incretins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The effect of dulaglutide on stroke: an exploratory analysis of the REWIND trial. https://app.cochat.ai/papers/10.1016/s2213-8587(19)30423-1
- The paper
- Gerstein, H. C., Hart, R., Colhoun, H. M., Diaz, R., Lakshmanan, M., Botros, F. T., Probstfield, J., Riddle, M. C., Rydén, L., Atisso, C. M., Dyal, L., Hall, S., Avezum, A., Basile, J., Conget, I., Cushman, W. C., Hancu, N., Hanefeld, M., Jansky, P., . . . Temelkova-Kurktschiev, T. (2020). The effect of dulaglutide on stroke: an exploratory analysis of the REWIND trial. The Lancet Diabetes & Endocrinology. https://doi.org/10.1016/s2213-8587(19)30423-1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.